Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034753237> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2034753237 endingPage "2392" @default.
- W2034753237 startingPage "2373" @default.
- W2034753237 abstract "The poly(ADP-ribose)polymerases (PARPs) catalyse the transfer of ADP-ribose units from the substrate NAD(+) to acceptor proteins, biosynthesising polyanionic poly(ADP-ribose) polymers. A major isoform, PARP-1, has been the target for design of inhibitors for over twenty-five years. Inhibitors of the activity of PARP-1 have been claimed to have applications in the treatment of many disease states, including cancer, haemorrhagic shock, cardiac infarct, stroke, diabetes, inflammation and retroviral infection, but only recently have PARP-1 inhibitors entered clinical trial. Most PARP-1 inhibitors mimic the nicotinamide of NAD(+) and the structure-activity relationships are understood in terms of the structure of the catalytic site. However, five questions remain if PARP-1 inhibitors are to realise their potential in treating human diseases. Firstly, the consensus pharmacophore is a benzamide with N-H conformationally constrained anti to the carbonyl-arene bond but this is also a pharmacophore for insolubility in water; can water-solubility be designed into inhibitors without loss of potency? Secondly, some potential clinical applications require tissue-selective PARP-1 inhibition; is this possible through pro-drug approaches? Thirdly, different diseases may require therapeutic PARP-1 inhibition to be either short-term or chronic; are there potential problems associated with chronic inhibition of this DNA-repair process? Fourthly, PARP-1 is one of at least eighteen isoforms; is isoform-selectivity essential, desirable or even possible? Fifthly, PARP activity can be inhibited in cells by inhibition of poly(ADP-ribose)-glycohydrolase (PARG); will this be a viable strategy for future drug design? The answers to these questions will determine the future of disease therapy through inhibition of PARP." @default.
- W2034753237 created "2016-06-24" @default.
- W2034753237 creator A5016634968 @default.
- W2034753237 creator A5027342897 @default.
- W2034753237 date "2005-09-01" @default.
- W2034753237 modified "2023-10-03" @default.
- W2034753237 title "Poly(ADP-ribose)polymerase Inhibition - Where Now?" @default.
- W2034753237 doi "https://doi.org/10.2174/0929867054864778" @default.
- W2034753237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16181138" @default.
- W2034753237 hasPublicationYear "2005" @default.
- W2034753237 type Work @default.
- W2034753237 sameAs 2034753237 @default.
- W2034753237 citedByCount "63" @default.
- W2034753237 countsByYear W20347532372012 @default.
- W2034753237 countsByYear W20347532372013 @default.
- W2034753237 countsByYear W20347532372014 @default.
- W2034753237 countsByYear W20347532372015 @default.
- W2034753237 countsByYear W20347532372016 @default.
- W2034753237 countsByYear W20347532372017 @default.
- W2034753237 countsByYear W20347532372018 @default.
- W2034753237 countsByYear W20347532372021 @default.
- W2034753237 crossrefType "journal-article" @default.
- W2034753237 hasAuthorship W2034753237A5016634968 @default.
- W2034753237 hasAuthorship W2034753237A5027342897 @default.
- W2034753237 hasConcept C181199279 @default.
- W2034753237 hasConcept C182979987 @default.
- W2034753237 hasConcept C185592680 @default.
- W2034753237 hasConcept C2779461342 @default.
- W2034753237 hasConcept C2779728014 @default.
- W2034753237 hasConcept C55493867 @default.
- W2034753237 hasConcept C56173144 @default.
- W2034753237 hasConcept C71240020 @default.
- W2034753237 hasConcept C75520062 @default.
- W2034753237 hasConcept C82381507 @default.
- W2034753237 hasConcept C86803240 @default.
- W2034753237 hasConcept C98274493 @default.
- W2034753237 hasConceptScore W2034753237C181199279 @default.
- W2034753237 hasConceptScore W2034753237C182979987 @default.
- W2034753237 hasConceptScore W2034753237C185592680 @default.
- W2034753237 hasConceptScore W2034753237C2779461342 @default.
- W2034753237 hasConceptScore W2034753237C2779728014 @default.
- W2034753237 hasConceptScore W2034753237C55493867 @default.
- W2034753237 hasConceptScore W2034753237C56173144 @default.
- W2034753237 hasConceptScore W2034753237C71240020 @default.
- W2034753237 hasConceptScore W2034753237C75520062 @default.
- W2034753237 hasConceptScore W2034753237C82381507 @default.
- W2034753237 hasConceptScore W2034753237C86803240 @default.
- W2034753237 hasConceptScore W2034753237C98274493 @default.
- W2034753237 hasIssue "20" @default.
- W2034753237 hasLocation W20347532371 @default.
- W2034753237 hasLocation W20347532372 @default.
- W2034753237 hasOpenAccess W2034753237 @default.
- W2034753237 hasPrimaryLocation W20347532371 @default.
- W2034753237 hasRelatedWork W1978367221 @default.
- W2034753237 hasRelatedWork W1980647462 @default.
- W2034753237 hasRelatedWork W1988201701 @default.
- W2034753237 hasRelatedWork W2016517525 @default.
- W2034753237 hasRelatedWork W2021766920 @default.
- W2034753237 hasRelatedWork W2040556202 @default.
- W2034753237 hasRelatedWork W2050371981 @default.
- W2034753237 hasRelatedWork W2089331401 @default.
- W2034753237 hasRelatedWork W2147736715 @default.
- W2034753237 hasRelatedWork W2259895594 @default.
- W2034753237 hasVolume "12" @default.
- W2034753237 isParatext "false" @default.
- W2034753237 isRetracted "false" @default.
- W2034753237 magId "2034753237" @default.
- W2034753237 workType "article" @default.